Heparan-N-sulfatase (Sulfamidase) (SGSH)

Heparan-N-sulfatase, also known as sulfamidase, is a critical lysosomal enzyme involved in the stepwise degradation of the glycosaminoglycan heparan sulfate. It specifically catalyzes the hydrolysis of N-sulfated glucosamine residues, a necessary step for the subsequent action of other lysosomal hydrolases (UniProt: P51688). The interaction between this enzyme and its substrate, heparan sulfate glycosaminoglycans, is the fundamental biochemical process disrupted in Mucopolysaccharidosis type IIIA (MPS IIIA or Sanfilippo syndrome A) (NCBI Gene: 6448). Mutations in the SGSH gene lead to a deficiency in enzymatic activity, resulting in the toxic lysosomal accumulation of partially degraded heparan sulfate. This accumulation is particularly damaging to the central nervous system, leading to progressive neurodegeneration, loss of motor function, and early childhood mortality (PubMed: 21922615). Therapeutic strategies focus on restoring enzymatic activity through enzyme replacement therapy (ERT) or gene therapy. While ERT aims to provide the functional enzyme systemically or intrathecally, gene therapy seeks to provide a long-term genetic fix by delivering a functional copy of the SGSH gene directly to the affected tissues (PubMed: 31203786).

The primary mechanism of action for drugs targeting this enzyme is enzyme replacement therapy (ERT), where recombinant human sulfamidase is administered to perform the catalytic degradation of accumulated heparan sulfate. Additionally, gene therapy approaches utilize viral vectors (e.g., AAV) to deliver a functional SGSH gene to patient cells, enabling the endogenous production of the enzyme to address both systemic and neurological manifestations of the deficiency.